Delivery Order SPE2DB24D3013-SPE2DB25FFPGR
- Not listed
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran...
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency (DLA) awarded a $22,848.80 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by August 5, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $14,218.96 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. The contract, which is non-set-aside and competitively awarded, has an ultimate completion date of August 11, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency has awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens. The award, issued on July 30, 2025, represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $6,060.69 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,447.52 for Dupixent 300 mg/2 ml pen (2 ml) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical prime vendor agreement running through December 2026. The place of performance is...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPGRDelivery Order
The Defense Logistics Agency awarded a $3,480.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-competitive delivery order represents a single pharmaceutical product shipment to support federal medical procurement needs. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026, which enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Dupixent (dupilumab) is a biologic medication used to treat conditions including moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma, indicating this delivery order supports Defense Health Agency and military treatment facility requirements for specialized immunological therapies. AmerisourceBergen's demonstrated portfolio of federal contract awards reflects its capability to fulfill diverse pharmaceutical and medical supply needs across multiple therapeutic domains through open competition. The company serves as a critical logistics partner for the Department of Defense medical supply chain, with its extensive network supporting military and veteran healthcare systems across multiple geographic regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 8/12/25 |